Acorai developed breakthrough non-invasive heart monitor device. The device enables the assessment of diastolic pulmonary artery pressure (dPAP), systolic pulmonary artery pressure (sPAP), and mean pulmonary artery pressure (mPAP) in Stage C Heart Failure patients undergoing recommended haemodynamic monitoring.
This device boasts a distinctive and patented hardware technology, coupled with an exclusive machine learning system, rendering it the first of its kind in the medical landscape.
The novel non-invasive intracardiac pressure monitoring (IPCM) device represents a significant leap forward in the assessment and management of heart failure (HF).
By harnessing its non-invasive nature, the IPCM device allows healthcare practitioners to gain unprecedented insights into intracardiac pressures without the need for invasive procedures.
This pioneering device is strategically designed to complement the expertise of qualified healthcare professionals (HCPs), positioning it as an invaluable companion test in the realm of cardiovascular care.
Acorai has obtainted the breakthrough device designation from the FDA for their non-invasive intracardiac pressure monitor.
